Micamlo Launched in Japan

barbara.lempert

Launch of ’s First High-Dose ARB and CCB Combination:”® Combination Tablets BP” - powerful antihypertensive effect lasting 24 hours due to unique “delta-lock1” structure -
May 31, 2013

Tokyo Japan, May 31, 2013 – Nippon Boehringer Ingelheim Co., Ltd. (headquartered in Shinagawa-ku, Tokyo; president, Yoshiaki Aono; hereinafter referred to as “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (Tokyo:4503, headquartered in Chuo-ku, Tokyo; president, Yoshihiko Hatanaka; hereinafter referred to as “Astellas”) announced today’s launch of “Micamloâ Combination Tablets BP,” a combination drug of telmisartan 80 mg, a long-acting angiotensin II type 1 (AT1) receptor blocker (ARB), and amlodipine 5 mg, a long-acting calcium channel blocker (CCB), following its drug price listing today.

Micamloâ Combination Tablets BP is Japan’s first combination of high-dose ARB and long-acting CCB. While the previously Micamloâ Combination Tablets AP is a combination drug of telmisartan 40 mg and amlodipine 5 mg, the amount of telmisartan in Micamloâ Combination Tablets BP is increased to 80 mg. This is, therefore, expected to maintain a more potent antihypertensive effect for 24 hours compared to existing ARB/CCB combination tablets.

The medicine expert of the domestic clinical studies of Micamloâ Combination Tablets BP, Dr. Jitsuo Higaki of the Department of Cardiology, Pulmonology, Hypertension and Nephrology at Ehime University Graduate School of Medicine, made a following comment: Unlike other ARBs, Micardisâ contained in “Micamloâ Combination Tablets BP contains Micardisâ has a special feature of providing powerful antihypertensive effect due to the delta-lock1 structure which binds with the stronger affinity to three points of AT1 receptor. It is also long-acting, with an effect that is sustained for 24 hours. Moreover, since the selective PPARγ-activating action of Micardis has a salutary effect upon metabolism, this drug…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS